Matt Sagan/X
Jun 17, 2025, 06:53
Matt Sagan: It’s a Great Time to Be Now in the Cancer Vaccines Space
Matt Sagan, Founder, Managing Partner and CEO of MoD Partners and Executive Director of BioForum Accelerator, shared a post on X:
“Great story to share and learn from it CureVac to be acquired by BioNTech in a public exchange offer for all shares of CureVac.
Acquisition of CureVac will complement BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing.
In fact CureVac was the one Donald Trump was shouting in early days of Covid19 pandemic US Government has to buy and German Government protected it.
CureVac has a great science, one clinical target in mRNA Cancer Vaccines several discovery targets and few preventive vaccines for infectious diseases in Phase 1 or Phase 2.
And now has been valued solid $1.25b representing a premium of 55% to CureVac’s three-month volume weighted average price.
Its great time to be now in the Cancer Vaccines space.
Race is on, different modalities and several partnering or M and A deals recently made.
Time to build on it!
Time to build one in Poland as well!”
More posts featuring Matt Sagan on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 17, 2025, 06:53
Jun 17, 2025, 06:49
Jun 17, 2025, 06:44
Jun 17, 2025, 06:28
Jun 17, 2025, 06:19
Jun 17, 2025, 06:11